AWM
VRTX icon

Affinity Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Affinity Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,525
Closed -$1.02M – 106
2019
Q1 		$1.02M Buy
+5,525
New +$1.02M 0.4% 41

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Affinity Wealth Management's VRTX Position: Q2 2019 in Review

Affinity Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 5,525 shares — an estimated $1.02M sold.

Affinity Wealth Management first reported a position in VRTX in Q1 2019 and held it in 1 quarter. The position peaked at $1.02M in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

  • Affinity Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Affinity Wealth Management sold 5,525 Vertex Pharmaceuticals shares in Q2 2019, an estimated $1.02M.
  • Affinity Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Affinity Wealth Management's Vertex Pharmaceuticals position peaked at $1.02M in Q1 2019.
  • 716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Affinity Wealth Management's 13F filing for Q2 2019, filed 24 Jul 2019.